272 related articles for article (PubMed ID: 27604143)
1. NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation.
García-Carpizo V; Sarmentero J; Han B; Graña O; Ruiz-Llorente S; Pisano DG; Serrano M; Brooks HB; Campbell RM; Barrero MJ
Sci Rep; 2016 Sep; 6():32952. PubMed ID: 27604143
[TBL] [Abstract][Full Text] [Related]
2. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.
Kuo AJ; Cheung P; Chen K; Zee BM; Kioi M; Lauring J; Xi Y; Park BH; Shi X; Garcia BA; Li W; Gozani O
Mol Cell; 2011 Nov; 44(4):609-20. PubMed ID: 22099308
[TBL] [Abstract][Full Text] [Related]
3. Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.
Wang J; Duan Z; Nugent Z; Zou JX; Borowsky AD; Zhang Y; Tepper CG; Li JJ; Fiehn O; Xu J; Kung HJ; Murphy LC; Chen HW
Cancer Lett; 2016 Aug; 378(2):69-79. PubMed ID: 27164560
[TBL] [Abstract][Full Text] [Related]
4. High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.
Coussens NP; Kales SC; Henderson MJ; Lee OW; Horiuchi KY; Wang Y; Chen Q; Kuznetsova E; Wu J; Chakka S; Cheff DM; Cheng KC; Shinn P; Brimacombe KR; Shen M; Simeonov A; Lal-Nag M; Ma H; Jadhav A; Hall MD
J Biol Chem; 2018 Aug; 293(35):13750-13765. PubMed ID: 29945974
[TBL] [Abstract][Full Text] [Related]
5. Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.
Yang P; Guo L; Duan ZJ; Tepper CG; Xue L; Chen X; Kung HJ; Gao AC; Zou JX; Chen HW
Mol Cell Biol; 2012 Aug; 32(15):3121-31. PubMed ID: 22645312
[TBL] [Abstract][Full Text] [Related]
6. SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic
Chong PSY; Chooi JY; Lim JSL; Toh SHM; Tan TZ; Chng WJ
Cancer Res; 2021 May; 81(9):2332-2344. PubMed ID: 33602783
[TBL] [Abstract][Full Text] [Related]
7. 5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
Wang S; Yang H; Su M; Lian F; Cong Z; Wei R; Zhou Y; Li X; Zheng X; Li C; Fu X; Han X; Shi Q; Li C; Zhang N; Geng M; Liu H; Li J; Huang X; Wang J
Eur J Med Chem; 2021 Oct; 222():113592. PubMed ID: 34147909
[TBL] [Abstract][Full Text] [Related]
8. A PWWP Domain of Histone-Lysine N-Methyltransferase NSD2 Binds to Dimethylated Lys-36 of Histone H3 and Regulates NSD2 Function at Chromatin.
Sankaran SM; Wilkinson AW; Elias JE; Gozani O
J Biol Chem; 2016 Apr; 291(16):8465-74. PubMed ID: 26912663
[TBL] [Abstract][Full Text] [Related]
9. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
10. NSD2 as a Promising Target in Hematological Disorders.
Azagra A; Cobaleda C
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232375
[TBL] [Abstract][Full Text] [Related]
11. NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis.
Sengupta D; Zeng L; Li Y; Hausmann S; Ghosh D; Yuan G; Nguyen TN; Lyu R; Caporicci M; Morales Benitez A; Coles GL; Kharchenko V; Czaban I; Azhibek D; Fischle W; Jaremko M; Wistuba II; Sage J; Jaremko Ł; Li W; Mazur PK; Gozani O
Mol Cell; 2021 Nov; 81(21):4481-4492.e9. PubMed ID: 34555356
[TBL] [Abstract][Full Text] [Related]
12. Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma.
Cheong CM; Mrozik KM; Hewett DR; Bell E; Panagopoulos V; Noll JE; Licht JD; Gronthos S; Zannettino ACW; Vandyke K
Cancer Lett; 2020 Apr; 475():99-108. PubMed ID: 32014459
[TBL] [Abstract][Full Text] [Related]
13. NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma.
Huang Z; Wu H; Chuai S; Xu F; Yan F; Englund N; Wang Z; Zhang H; Fang M; Wang Y; Gu J; Zhang M; Yang T; Zhao K; Yu Y; Dai J; Yi W; Zhou S; Li Q; Wu J; Liu J; Wu X; Chan H; Lu C; Atadja P; Li E; Wang Y; Hu M
Cancer Res; 2013 Oct; 73(20):6277-88. PubMed ID: 23980095
[TBL] [Abstract][Full Text] [Related]
14. Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.
Huang X; LeDuc RD; Fornelli L; Schunter AJ; Bennett RL; Kelleher NL; Licht JD
J Biol Chem; 2019 Aug; 294(33):12459-12471. PubMed ID: 31248990
[TBL] [Abstract][Full Text] [Related]
15. Screening for histone codebreakers.
Bedford MT
J Biol Chem; 2018 Aug; 293(35):13766-13767. PubMed ID: 30171150
[TBL] [Abstract][Full Text] [Related]
16. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z
Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584
[TBL] [Abstract][Full Text] [Related]
17. Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling.
Wang JJ; Zou JX; Wang H; Duan ZJ; Wang HB; Chen P; Liu PQ; Xu JZ; Chen HW
Acta Pharmacol Sin; 2019 Aug; 40(8):1067-1075. PubMed ID: 30670815
[TBL] [Abstract][Full Text] [Related]
18. In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L.
Morishita M; Mevius D; di Luccio E
BMC Struct Biol; 2014 Dec; 14():25. PubMed ID: 25494638
[TBL] [Abstract][Full Text] [Related]
19. The histone methyltransferase, NSD2, enhances androgen receptor-mediated transcription.
Kang HB; Choi Y; Lee JM; Choi KC; Kim HC; Yoo JY; Lee YH; Yoon HG
FEBS Lett; 2009 Jun; 583(12):1880-6. PubMed ID: 19481544
[TBL] [Abstract][Full Text] [Related]
20. The NSD family of protein methyltransferases in human cancer.
Vougiouklakis T; Hamamoto R; Nakamura Y; Saloura V
Epigenomics; 2015 Aug; 7(5):863-74. PubMed ID: 25942451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]